Interpace Biosciences Salute del bilancio
Salute finanziaria criteri di controllo 2/6
Interpace Biosciences has a total shareholder equity of $-12.5M and total debt of $6.8M, which brings its debt-to-equity ratio to -54.3%. Its total assets and total liabilities are $13.0M and $25.5M respectively. Interpace Biosciences's EBIT is $4.4M making its interest coverage ratio 5. It has cash and short-term investments of $2.0M.
Informazioni chiave
-54.3%
Rapporto debito/patrimonio netto
US$6.78m
Debito
| Indice di copertura degli interessi | 5x |
| Contanti | US$2.02m |
| Patrimonio netto | -US$12.49m |
| Totale passività | US$25.46m |
| Totale attività | US$12.97m |
Aggiornamenti recenti sulla salute finanziaria
Analisi della posizione finanziaria
Passività a breve termine: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passività a lungo termine: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: IDXG has negative shareholder equity, which is a more serious situation than a high debt level.
Riduzione del debito: IDXG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Copertura del debito: IDXG's debt is well covered by operating cash flow (52.9%).
Copertura degli interessi: IDXG's interest payments on its debt are well covered by EBIT (5x coverage).